Check out your Company Bowl for anonymous work chats.
Sartorius closed the first half of the year with a positive trend in sales revenue development. Due to the ongoing high volatility and limited predictability, however, the company is now de-risking its outlook for the second half of the year. "Sartorius met its targets for the first half of the year, and we achieved the intended slight sales revenue growth and robust profitability in the second quarter. As in the first three months, the picture remained exceptionally mixed," said CEO Joachim Kreuzburg. "In the medium and long term, the mega topics of hashtag#healthcare and hashtag#biotechnology remain strong structural drivers for our profitable growth strategy, and the increased volatility caused by the pandemic has not made any difference to this.” ➡️ Moderately positive revenue development in Q2 ➡️ Demand recovery remains muted ➡️ Full-year outlook deliberately more cautious ➡️ Long-term trends in life sciences & biopharma remain positive Read media release: https://lnkd.in/emm-3rNs
Transforming water use in filter production: Potential to save over 50 million liters annually. Filter production demands significant amounts of purified water. Ghiath Wahbi, Project Manager for Separation Technologies, and his team introduced a prototype for a water recycling system for filter production, enabling the reuse of the vital resource. This invention can not only conserve water but also reduce energy costs and carbon emissions. Discover more about this innovative project on the Sartorius blog: https://ow.ly/pq4v50SwSVC
Heart failure affects an estimated 40 to 60 million individuals globally. Find out how Sartorius and the biotech company Repairon are hashtag#InThisTogether for a cure Shortly after birth, our heart muscle cells lose their ability to divide. This means that damage such as a heart attack leads to an irreversible loss of these cells. As a result, the heart's ability to pump effectively decreases, which can lead to heart failure. For over two decades, the team at Repairon has been researching to develop the so-called heart patch. This new heart tissue is artificially grown from stem cells in the lab and then sewn onto special membranes compatible with the human body. Discover how Sartorius supports Repairon in the production of stem cells for heart patches on the Sartorius Blog: https://ow.ly/gPXZ50Svinq
Recapping Pride Month!🌈 As June, dedicated to celebrating the LGBTQ+ community, comes to an end, we would like to spotlight the activities that employee resource groups at Sartorius organized and hosted. Highlights of this year’s Pride Month: - Participation in the Long Island Pride Parade - Pride Celebration and Employee Appreciation Party - Virtual Panel Discussion with participants from Sartorius’ sites around the world All events had one goal: to focus on the LGBTQ+ community, raise awareness of their challenges, and promote a culture of diversity, equity, belonging, and inclusion within the company. Read more about the events on the Sartorius blog: https://sar.to/njtvo
Have you ever heard of the mosquito-borne chikungunya virus? According to the WHO, more than two million cases of chikungunya infections, which cause flu-like symptoms and severe joint pain, have been reported since 2005. No vaccine was available against the virus – until Sartorius’ customer Valneva had their vaccine approved by the FDA in late 2023. Learn more on the Sartorius blog about how we are part of the solution and how recombinant albumin from Albumedix now a part of Sartorius, stabilizes the vaccine during storage and transport: https://sar.to/voytu
Is time of the essence? The clocks are ticking louder for scientists and engineers researching new treatments for cancer, genetic disorders, and the pandemics of tomorrow. Moving quickly from discovering to delivering biological therapeutics can make or break its success. Sartorius’ single-use technologies are a speed boost, cutting production time and costs, while enhancing flexibility. This empowers research teams around the world to simplify and accelerate progress in life science and bioprocessing. We’re in this together. Expedite your drug to market through rapid deployment of single-use solutions. Discover our scalable single-use technologies at www.sartorius.com
Striving towards making a positive impact on UN sustainability goal number 3 – health and well-being? Scientists worldwide are tirelessly working to discover new solutions against cancer, inheritable diseases, and future pandemics. Sartorius supports them with cutting-edge technologies that help translate scientific discoveries into effective therapies more quickly. So that patients get the treatments they need. In doing so, together, we are making an impact to “health and well-being”. We're in this together. Our innovations enable you to provide more people with access to better healthcare. Let's join forces and improve social sustainability and more at www.sartorius.com
Construction completed in Ann Arbor! Two years after breaking ground in the Tech Loop at Research Park, Sartorius today celebrates the opening of its new Center of Excellence for Bioanalytics in Ann Arbor, Hashtag#Michigan, USA. The 130,000-square-foot facility houses a modern manufacturing and services area, biology labs, a warehouse, office and training spaces, as well as a Customer Interaction Center (CIC). It was built with a focus on sustainability. "Sartorius is a leading provider of highly automated bioanalytical solutions that are used in the discovery and development of innovative biopharmaceutical drugs. With our new flagship site in Ann Arbor, we are bringing together our core competencies and dedicated experts under one roof, further strengthening our ability to address key customer needs in this highly innovative and relevant field," said Dr. Alexandra Gatzemeyer, Head of the Lab Products & Services division and member of the Executive Board of Sartorius. Read media release: https://sar.to/pi1xz
Join us in celebrating German Diversity Day and echoing the “Voice for Diversity” – this year’s motto. Together with the Charta der Vielfalt e.V. and their members and signatories, we're committed to fostering diversity in the workplace and elevating the conversation about its value. Each of the 14,600 voices at Sartorius brings in a unique tone and we believe that the mix of cultures, genders, identities, ages, educational backgrounds, and more leads to better solutions for our life science and biopharma customers. Learn more about diversity at our company: https://sar.to/0817n
On the path to gender parity, our sites in France are well on track with a proportion of 49% women and 51% men. And in China, with 47% the percentage is also quite high. Across the entire company, 5,994 women at Sartorius are united by the ambition to help translate scientific discoveries into real-world medicine faster: from engineers, to scientists, to IT professionals. Let’s take a look at our management levels: In 2023, Alexandra Gatzemeyer was the first woman to join the four-member Executive Board at Sartorius. All in all, 31% of people in leadership positions both directly below the Board level and on the second management level at Sartorius are female. With these numbers, the company is well on its way to meeting its target of having one-third women at the two management levels below the Executive Board by the end of 2025. And did you know that our employee resource groups, such as the Sartorius Business Women's Association or the LGBT+ Friends Alliance, foster gender parity and increase visibility and acceptance of employees regardless of gender, expression or identity? Learn more about diversity at Sartorius: www.sartorius.com/diversity
